title: Cerebrospinal fluid free choline in movement disorders of paediatric onset.
abstract: We measured free choline in cerebrospinal fluid (CSF) of 78 patients with movement disorders of paediatric onset and various controls as a putative index of central phospholipid metabolism. Most of the disorders studied were myoclonic disorders, such as progressive myoclonus epilepsy, the opsoclonus-myoclonus syndrome, and essential myoclonus, but other movement disorders, interictal seizure disorders, and different neurological and nonneurological disorders were also included. There were no significant differences in CSF choline concentrations in myoclonic disorders or other movement disorders compared with controls. The CSF choline levels were lowest in children with seizure disorders including progressive myoclonus epilepsy. In progressive myoclonus epilepsy, the CSF choline values resembled other epileptic disorders rather than other myoclonic disorders. When all the data were analysed collectively, no significant relation of CSF choline was found to patient age, gender, aliquot of CSF measured, or the length of time the sample was stored at -70 degrees C. Separate analyses of data from children and adults showed a trend toward a biphasic relation between patient age and CSF choline which could be pursued in developmental studies of normal subjects. Reduced CSF choline may indicate increased choline incorporation into brain phospholipids, disturbances of choline metabolism, decreased choline release, or non-neural factors.
authors.affiliation: National Pediatric Myoclonus Center, Washington, DC 20004, USA.
authors.forename: M R
authors.initials: MR
authors.lastname: Pranzatelli
authors.forename: I
authors.initials: I
authors.lastname: Hanin
authors.forename: E
authors.initials: E
authors.lastname: Tate
authors.forename: G
authors.initials: G
authors.lastname: Kindel
authors.forename: A
authors.initials: A
authors.lastname: Bergin
authors.forename: C M
authors.initials: CM
authors.lastname: Brown
authors.forename: P
authors.initials: P
authors.lastname: Habersang
authors.forename: R
authors.initials: R
authors.lastname: Habersang
authors.forename: K J
authors.initials: KJ
authors.lastname: Mack
authors.forename: B
authors.initials: B
authors.lastname: Rosenbaum
authors.forename: K A
authors.initials: KA
authors.lastname: Selby
authors.forename: M
authors.initials: M
authors.lastname: Vasconcellos
mesh_terms: D000109:Acetylcholine / Q000134:cerebrospinal fluid; D000324:Adrenocorticotropic Hormone / Q000627:therapeutic use; D000328:Adult; D002648:Child; D002675:Child, Preschool; D002794:Choline / Q000134:cerebrospinal fluid*; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D018450:Disease Progression; D004831:Epilepsies, Myoclonic / Q000134:cerebrospinal fluid / Q000150:complications; D005260:Female; D006801:Humans; D008297:Male; D009069:Movement Disorders / Q000134:cerebrospinal fluid* / Q000150:complications / Q000188:drug therapy; D010743:Phospholipids / Q000378:metabolism
chemical_list: D010743:Phospholipids; D000324:Adrenocorticotropic Hormone; D002794:Choline; D000109:Acetylcholine